2030 target questions standard called signs campaign resigned results patients focused leqembi difference snider committee ceo leader irregularities aducanumab months loss sales hard offers eisai health process federal financial effective

Articles for Aduhelm, search results for medicare

Medicare limits coverage of $28,000-a-year Alzheimer’s drug
2 years, 11 months ago

Medicare limits coverage of $28,000-a-year Alzheimer’s drug

Associated Press  

WASHINGTON — Medicare said Tuesday it will limit coverage of a $28,000-a-year Alzheimer’s drug whose benefits have been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices. “CMS has been and remains committed to providing the American public with a clear, trusted, evidence-based decision …

Disease Medicare Patients Price Company Clinical Trials Drug
Medicare limits coverage of $28,000-a-year Alzheimer’s drug
2 years, 11 months ago

Medicare limits coverage of $28,000-a-year Alzheimer’s drug

LA Times  

Medicare said Tuesday it will limit coverage of a $28,000-a-year Alzheimer’s drug whose benefits have been widely questioned, a major development in the nation’s tug-of-war over the fair value of new medicines that offer tantalizing possibilities but come with prohibitive prices. “Alzheimer’s disease is a devastating illness that has touched the lives of millions of American families,” Medicare administrator Chiquita …

Disease Medicare Patients Price Clinical Trials Drug Fda
Alzheimer’s drug Aduhelm is a key factor driving up Medicare premiums
3 years, 1 month ago

Alzheimer’s drug Aduhelm is a key factor driving up Medicare premiums

CNN  

CNN — When the US Food and Drug Administration approved a costly new drug for Alzheimer’s disease, Aduhelm, earlier this year, experts warned that all of Medicare’s more than 63 million enrollees could wind up paying the price. “This does show how just one drug could have a major impact on spending and premiums,” said Tricia Neuman, executive director of …

Medicare Premium Spending Drug Fda Cms Aduhelm
Column: How the FDA’s lousy judgment and a greedy drug company combined to hit Medicare members hard
3 years, 1 month ago

Column: How the FDA’s lousy judgment and a greedy drug company combined to hit Medicare members hard

LA Times  

The fallout from the Food and Drug Administration’s hasty approval of a new Alzheimer’s drug in June was predicted to be severe: Excessive pricing for a drug lacking strong evidence of effectiveness would impose heavy costs on the healthcare system nationwide, especially on Medicare. The coverage determination process is still underway, but Medicare officials said they’re duty-bound to “plan for …

Medicare Drugs Social Security Patients Premium Drug Members
Aduhelm: The hard math on the new $56,000 Alzheimer’s drug
3 years, 5 months ago

Aduhelm: The hard math on the new $56,000 Alzheimer’s drug

CNN  

A version of this story appeared in CNN’s What Matters newsletter. To get it in your inbox, sign up for free here CNN — The new Alzheimer’s drug Aduhelm costs $56,000 per person, per year – so much that it would affect the economics of Medicare. “In all studies in which it was evaluated, however, Aduhelm consistently and very convincingly …

Disease Treatment Medicare Clinical Trials Cost Cnn Drug
Column: The FDA’s hasty approval of a new Alzheimer’s drug is looking worse than ever
3 years, 6 months ago

Column: The FDA’s hasty approval of a new Alzheimer’s drug is looking worse than ever

LA Times  

Following a year in which the Food and Drug Administration meekly allowed President Trump to denigrate its integrity and undermine its judgment, it wasn’t clear that the agency could fall even lower in public and professional esteem. The FDA’s widely criticized decision on June 7 to approve the new Alzheimer’s drug Aduhelm despite a nearly complete absence of evidence that …

Medicare Drugs Patients Spending Drug Fda Health Spending
Medicare copays for new Alzheimer’s drug could reach $11,500
3 years, 6 months ago

Medicare copays for new Alzheimer’s drug could reach $11,500

Associated Press  

WASHINGTON — A new $56,000-a-year Alzheimer’s drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Thursday. “At this price, the cost of this one drug alone could top all others covered by Medicare, if it is used widely,” said Tricia Neuman, coauthor …

Medicare Price Drug Fda Medication Biogen Aduhelm
Medicare Copays For New Alzheimer's Drug Could Reach $11,500 Annually
3 years, 6 months ago

Medicare Copays For New Alzheimer's Drug Could Reach $11,500 Annually

NPR  

Medicare Copays For New Alzheimer's Drug Could Reach $11,500 Annually Enlarge this image toggle caption Biogen via AP Biogen via AP WASHINGTON — A new $56,000-a-year Alzheimer's drug would raise Medicare premiums broadly, and some patients who are prescribed the medication could face copayments of about $11,500 annually, according to a research report published Thursday. "At this price, the cost …

Medicare Price Drug Fda Kaiser Biogen Aduhelm